- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00056004
Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
Phase II Trial Of Zileuton In Persons With Bronchial Dysplasia
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of zileuton may be an effective way to prevent lung cancer in patients who have bronchial dysplasia.
PURPOSE: Randomized phase II trial to study the effectiveness of zileuton in preventing lung cancer in patients who have bronchial dysplasia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine the efficacy of zileuton, in terms of number of sites and grade of dysplastic lesions in the bronchial epithelium, in patients with documented bronchial dysplasia.
- Correlate the regression of bronchial dysplasia (number and grade) and improvement in sputum cytology with the modulation of molecular biomarkers in patients treated with this drug.
- Determine the overall toxicity of this drug in these patients.
- Determine the 6-month natural history of bronchial dysplasia in patients who are randomized to receive treatment with a placebo.
OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to smoking status (current vs recently quit smoker), and prior cancer (none vs lung or head and neck). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral zileuton 4 times daily for 6 months in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive oral placebo 4 times daily for 6 months in the absence of disease progression or unacceptable toxicity.
Patients are followed at 4 weeks.
PROJECTED ACCRUAL: Approximately 134 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201-1379
- Barbara Ann Karmanos Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
At high risk for dysplasia, defined by 1 of the following criteria:
Current or former smokers who have smoked at least 30 pack-years
- Former smokers must be enrolled within 20 years of complete smoking cessation
- Patients with curatively treated stage I non-small cell lung cancer*
- Patients with curatively treated stage I or II squamous cell carcinoma of the head and neck (limited to oral cavity, pharynx, or larynx)* NOTE: *At least 12 months post-curative therapy
Histologic confirmation of mild to severe bronchial dysplasia on bronchoscopic biopsy required
- Moderate or severe atypia on sputum cytology required before bronchoscopy (not required for patients with prior lung or head and neck cancer)
- No evidence of malignancy by chest x-ray
PATIENT CHARACTERISTICS:
Age
- 18 and over (for patients with prior lung or head and neck malignancy)
- 35 and over (for all other patients)
Performance status
- SWOG 0-1
Life expectancy
- Not specified
Hematopoietic
- WBC at least 3,000/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10.0 g/dL
- No bleeding disorder
Hepatic
- Bilirubin no greater than upper limit of normal (ULN)
- Liver enzymes no greater than ULN
- PT/PTT no greater than ULN
- No active or chronic liver disease (even if transaminases have normalized)
Renal
- Creatinine no greater than ULN
Cardiovascular
- No unstable angina
- No uncontrolled heart failure
Pulmonary
- No significant asthma or chronic obstructive pulmonary disease requiring chronic or periodic (at least once per year) steroids for flares
- No acute or chronic respiratory failure
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Willing and able to undergo serial bronchoscopic examinations
- No ongoing alcohol use (i.e., at least 1 glass of wine, beer, or a mixed drink per day on a regular basis)
- No other medical condition that would preclude safety during study participation
- No other active or invasive malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix
- No hypersensitivity to study drug or any of its inactive ingredients
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- More than 3 months since prior corticosteroids*
- No concurrent corticosteroids*
- No concurrent anticancer hormonal agents NOTE: *Systemic or inhaled, including chronic administration
Radiotherapy
- No concurrent radiotherapy
Surgery
- Not specified
Other
- More than 3 months since prior lipoxygenase inhibitors*
- More than 3 months since prior investigational agents
- More than 3 months since prior nutritional supplements (except 1 daily multivitamin)
- No concurrent nutritional supplements (except 1 daily multivitamin)
- No other concurrent lipoxygenase inhibitors*
- No other concurrent investigational agents
- No concurrent warfarin, beta-blockers, or theophylline
- No other concurrent antineoplastic agents
No concurrent or chronic daily use of non-steroidal anti-inflammatory agents (NSAIDS) (except cardioprotective doses of aspirin less than 100 mg/day)
- Periodic use of NSAIDS allowed
- Concurrent participation in a smoking cessation program (including use of bupropion or nicotine gum or patch) allowed NOTE: *Systemic or inhaled, including chronic administration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Bronchial dysplasia number and grade at 6 months
|
Secondary Outcome Measures
Outcome Measure |
---|
Biomarkers (Ki-67, Cyclin D1, bcl-2, bax, caspase-3) by immunohistochemistry at 6 and 12 months
|
Biomarkers (5-HETE, LTB-4) by blood and BAL levels at 6 and 12 months
|
Adverse events as measured by number and severity monthly
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- non-small cell lung cancer
- stage I non-small cell lung cancer
- stage I squamous cell carcinoma of the lip and oral cavity
- stage II squamous cell carcinoma of the lip and oral cavity
- stage I squamous cell carcinoma of the hypopharynx
- stage I squamous cell carcinoma of the larynx
- stage I squamous cell carcinoma of the nasopharynx
- stage I squamous cell carcinoma of the oropharynx
- stage II squamous cell carcinoma of the hypopharynx
- stage II squamous cell carcinoma of the larynx
- stage II squamous cell carcinoma of the nasopharynx
- stage II squamous cell carcinoma of the oropharynx
- small cell lung cancer
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Leukotriene Antagonists
- Hormone Antagonists
- Lipoxygenase Inhibitors
- Zileuton
Other Study ID Numbers
- CDR0000271915
- P30CA022453 (U.S. NIH Grant/Contract)
- WSU-D-2405
- WSU-093201MP4F
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on zileuton
-
University of Massachusetts, WorcesterBristol-Myers SquibbTerminatedChronic Myelogenous LeukemiaUnited States
-
Cornerstone Therapeutics Inc.Completed
-
Critical TherapeuticsTerminatedAsthmaUnited States
-
Critical TherapeuticsCompleted
-
Critical TherapeuticsCompleted
-
Gelb, Arthur F., M.D.Completed
-
University of MichiganNational Institutes of Health (NIH)CompletedIdiopathic Pulmonary FibrosisUnited States
-
Washington University School of MedicineDoris Duke Charitable FoundationCompletedLung InflammationUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed